Patents Assigned to BioCryst Pharmaceuticals, Inc.
-
Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
Patent number: 11866418Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.Type: GrantFiled: April 27, 2022Date of Patent: January 9, 2024Assignee: BioCryst Pharmaceuticals, Inc.Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng Lu, Minwan Wu, Wei Lv, Trung Xuan Nguyen, Zhao Dang, Venkat R. Chintareddy, V. Satish Kumar, Krishnan Raman -
Patent number: 11807605Abstract: Disclosed are compounds of formula I, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.Type: GrantFiled: July 13, 2021Date of Patent: November 7, 2023Assignee: BioCryst Pharmaceuticals, Inc.Inventors: Pravin L. Kotian, Yarlagadda S. Babu, V. Satish Kumar, Weihe Zhang, Lakshminarayana Vogeti
-
Patent number: 11708332Abstract: Disclosed are compounds of formula I as described herein, and pharmaceutically acceptable salts thereof. The compounds are disclosed to be inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.Type: GrantFiled: November 15, 2021Date of Patent: July 25, 2023Assignee: BioCryst Pharmaceuticals, Inc.Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Minwan Wu, Venkat R. Chintareddy, V. Satish Kumar, Weihe Zhang
-
Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
Patent number: 11708347Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.Type: GrantFiled: February 5, 2021Date of Patent: July 25, 2023Assignee: BioCryst Pharmaceuticals, Inc.Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng Lu, Minwan Wu, Wei Lv, Trung Xuan Nguyen, Zhao Dang, Venkat R. Chintareddy, V. Satish Kumar, Krishnan Raman -
Patent number: 11708333Abstract: Disclosed are compounds of formula I: as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one such compound, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.Type: GrantFiled: December 7, 2021Date of Patent: July 25, 2023Assignee: BioCryst Pharmaceuticals, Inc.Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Minwan Wu, Venkat R. Chintareddy, V. Satish Kumar, Weihe Zhang
-
Patent number: 11685721Abstract: Disclosed are compounds of formula I as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.Type: GrantFiled: November 9, 2021Date of Patent: June 27, 2023Assignee: BioCryst Pharmaceuticals, Inc.Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Minwan Wu, Venkat R. Chintareddy, V. Satish Kumar, Weihe Zhang
-
Patent number: 11661426Abstract: Disclosed are compounds of formula I, II, III, and IV, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of ALK2 kinase. Also provided are pharmaceutical compositions comprising a compound of formula I, II, III, or IV, or pharmaceutically acceptable salt thereof, and methods involving use of the compounds or pharmaceutically acceptable salts thereof and compositions in the treatment and prevention of various diseases and conditions, such as fibrodysplasia ossificans progressiva.Type: GrantFiled: June 14, 2018Date of Patent: May 30, 2023Assignee: BioCryst Pharmaceuticals, Inc.Inventors: Pravin L. Kotian, Yarlagadda S. Babu, V. Satish Kumar, Weihe Zhang, Peng-Cheng Lu, Krishnan Raman
-
Patent number: 11618731Abstract: Disclosed are compounds of formula I, II, and III, and pharmaceutically acceptable salts thereof, which are inhibitors of kallikrein. Also provided are pharmaceutical compositions comprising such a compound, and methods involving use of the compounds and compositions in the treatment and prevention of acquired or hereditary angioedema, or other diseases and conditions characterized by aberrant kallikrein activity.Type: GrantFiled: August 7, 2020Date of Patent: April 4, 2023Assignee: BioCryst Pharmaceuticals, Inc.Inventors: Pravin L. Kotian, Yarlagadda S. Babu, V. Satish Kumar, Venkat R. Chintareddy, Weihe Zhang, Lakshminarayana Vogeti
-
Patent number: 11618733Abstract: Disclosed are crystalline salts of Compound I, methods of preparing them, and related pharmaceutical preparations thereof. Also disclosed are methods of treatment using the crystalline salts of the invention.Type: GrantFiled: September 2, 2021Date of Patent: April 4, 2023Assignee: BioCryst Pharmaceuticals, Inc.Inventors: Yahya El-Kattan, Yarlagadda S. Babu
-
Patent number: 11559515Abstract: Disclosed are compounds of formula I, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising a compound of formula I, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by aberrant complement system activity.Type: GrantFiled: August 26, 2020Date of Patent: January 24, 2023Assignee: BioCryst Pharmaceuticals, Inc.Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Lakshminarayana Vogeti, Minwan Wu, Venkat R. Chintareddy, Krishnan Raman
-
Patent number: 11464755Abstract: The invention provides unit dosage forms, kits, and methods useful for treating viral infections.Type: GrantFiled: August 6, 2019Date of Patent: October 11, 2022Assignee: Biocryst Pharmaceuticals, Inc.Inventors: Yarlagadda S Babu, Pooran Chand, Shanta Bantia, Shane Arnold, John Michael Kilpatrick
-
Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
Patent number: 11370774Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.Type: GrantFiled: March 16, 2021Date of Patent: June 28, 2022Assignee: BioCryst Pharmaceuticals, Inc.Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng Lu, Minwan Wu, Wei Lv, Trung Xuan Nguyen, Zhao Dang, Venkat R. Chintareddy, V. Satish Kumar, Krishnan Raman -
Publication number: 20220160694Abstract: This disclosure is generally in the field of ophthalmic therapies, and more particularly to the treatment of various ocular diseases and conditions by non-surgical administration to the eye of a subject of a drug composition described herein containing a plasma kallikrein inhibitor. Plasma kallikrein inhibitors include avoralstat. The compositions and methods include delivery of a plasma kallikrein inhibitor to the suprachoroidal space (SCS) of the eye.Type: ApplicationFiled: April 8, 2020Publication date: May 26, 2022Applicant: BIOCRYST PHARMACEUTICALS, INC.Inventors: Yarlagadda Babu, Viral Kansara, Rick McElheny
-
Patent number: 11230530Abstract: Disclosed are compounds of formula I: as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one such compound, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.Type: GrantFiled: April 10, 2020Date of Patent: January 25, 2022Assignee: BioCryst Pharmaceuticals, Inc.Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Minwan Wu, Venkat R. Chintareddy, V. Satish Kumar, Weihe Zhang
-
Patent number: 11203574Abstract: Disclosed are compounds of formula I as described herein, and pharmaceutically acceptable salts thereof. The compounds are disclosed to be inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.Type: GrantFiled: March 24, 2020Date of Patent: December 21, 2021Assignee: BioCryst Pharmaceuticals, Inc.Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Minwan Wu, Venkat R. Chintareddy, V. Satish Kumar, Weihe Zhang
-
Patent number: 11192861Abstract: Disclosed are compounds of formula I as described herein, and pharmaceutically acceptable salts thereof. The compounds are disclosed to be inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.Type: GrantFiled: March 24, 2020Date of Patent: December 7, 2021Assignee: BioCryst Pharmaceuticals, Inc.Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Minwan Wu, Venkat R. Chintareddy, V. Satish Kumar, Weihe Zhang
-
Patent number: 11173159Abstract: The present invention is directed to methods and compositions for inhibition of viral nucleic acid polymerases, such as RNA and DNA polymerases, and methods and compositions that are useful for treating viral infections in subjects. The methods comprise administering to the subject a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, or a composition comprising a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier. The composition or method may optionally comprise one or more additional anti-viral agents.Type: GrantFiled: August 16, 2019Date of Patent: November 16, 2021Assignee: BioCryst Pharmaceuticals, Inc.Inventors: Shanta Bantia, Pravin L. Kotian, Yarlagadda S. Babu
-
Patent number: 11117867Abstract: Disclosed are crystalline salts of Compound I, methods of preparing them, and related pharmaceutical preparations thereof. Also disclosed are methods of treatment using the crystalline salts of the invention.Type: GrantFiled: February 6, 2020Date of Patent: September 14, 2021Assignee: BioCryst Pharmaceuticals, Inc.Inventors: Yahya El-Kattan, Yarlagadda S. Babu
-
Patent number: 11110092Abstract: The present application relates to treatment of hematologic cancers, which treatments can include, e.g., administration of a purine nucleoside phosphorylase (PNP) inhibitor, an alkylating agent and/or an anti-CD20 agent, and related compositions and kits.Type: GrantFiled: May 1, 2019Date of Patent: September 7, 2021Assignee: BIOCRYST PHARMACEUTICALS, INC.Inventors: Shanta Bantia, Philip Breitfeld, Yarlagadda S Babu
-
Patent number: 11066360Abstract: Disclosed are compounds of formula I, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.Type: GrantFiled: December 18, 2019Date of Patent: July 20, 2021Assignee: BioCryst Pharmaceuticals, Inc.Inventors: Pravin L. Kotian, Yarlagadda S. Babu, V. Satish Kumar, Weihe Zhang, Lakshminarayana Vogeti